Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: cyclosporine Clear all
Not listed No phase listed Observational

Genetic Predictors of Renal Dysfunction Following Heart Transplantation

NCT01686191
View directory record Official record
Conditions
Heart Transplantation, Chronic Renal Insufficiency
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

NCT02867800
View directory record Official record
Conditions
Sickle Cell Disease, Graft Versus Host Disease
Interventions
Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil
Drug · Procedure
Lead sponsor
Monica Bhatia
Other
Eligibility
3 Years to 20 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The COAT Trial: Cequa's Onset of Action Trial

NCT06482177
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine ophthalmic solution
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 19, 2026, 9:43 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

NCT00777400
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
Efalizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

NCT00099736
View directory record Official record
Conditions
Kidney Transplantation
Interventions
FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
42
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

NCT01231412
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hodgkin Lymphoma, Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Sirolimus, Total-Body Irradiation
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
6
States / cities
Denver, Colorado • Atlanta, Georgia • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

NCT01598987
View directory record Official record
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia

NCT02446964
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia in Complete Remission, Acute Myeloid Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Complete Remission
Interventions
Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Total Marrow Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 19, 2026, 9:43 AM EDT
Enrolling by invitation Phase 4 Interventional

Vevye + Flarex Combination Therapy for Dry Eye

NCT07553455
View directory record Official record
Conditions
Dry Eye
Interventions
Vevye(Cyclosporine 0.1% Ophthalmic Solution), Flarex
Drug
Lead sponsor
Canyon City Eyecare
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia

NCT00005801
View directory record Official record
Conditions
Leukemia
Interventions
therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Denver, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 19, 2026, 9:43 AM EDT
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

NCT03750383
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Cyclosporine, Prednisone
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 19, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Cyclophosphamide, BCNU, Etoposide, Filgrastim, Antithymocyte globulin, Cyclosporine, Mycophenolate mofetil, Rituximab, Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation, CD34+ Cells, Solu-Medrol
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV

NCT00084149
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, and Zidovudine, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Minneapolis, Minnesota • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of HSCT for Patients With High-risk Hemoglobinopathy Using a Nonmyeloablative Preparative Regimen

NCT00427661
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Hemoglobinopathies
Interventions
Busulfan; Fludarabine; cyclosporine A and MMF
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
3 Years to 35 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment

NCT00079183
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
sirolimus
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00044954
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
14
States / cities
Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 19, 2026, 9:43 AM EDT
No Longer Available No phase listed Expanded access

Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients

NCT00633373
View directory record Official record
Conditions
Lung Transplant
Interventions
Cyclosporine Inhalation Solution
Drug
Lead sponsor
APT Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
U.S. locations
8
States / cities
San Francisco, California • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 19, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

NCT02630563
View directory record Official record
Conditions
Pediatric Liver Transplantation
Interventions
Corticosteroids, Cyclosporine, mycophenolate mofetil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 12 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

NCT00064701
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
12 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

NCT00003145
View directory record Official record
Conditions
Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
Interventions
Fludarabine Phosphate, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Cyclosporine, Mycophenolate Mofetil, Therapeutic Allogeneic Lymphocytes, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cyclosporine For The Treatment Of COVID-19(+)

NCT04492891
View directory record Official record
Conditions
SARS (Disease)
Interventions
Cyclosporine, Standard of Care Treatment
Drug · Other
Lead sponsor
Bryan Burt, MD
Other
Eligibility
18 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 19, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies

NCT00079391
View directory record Official record
Conditions
Hematologic Malignancies, Bone Marrow Transplant Rejection
Interventions
allogeneic hematopoietic stem cell transplantation
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 19, 2026, 9:43 AM EDT